Using virus-specific T-cells to treat infections after stem cell transplants
Allogeneic virus-specific T-cell therapy after hematopoietic stem cell transplant: determinants of treatment success and failure
This study is looking at how special immune cells from healthy donors can help children who have had a stem cell transplant fight off certain viral infections, making it easier for their bodies to recover than with regular medicine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11174371 on NIH RePORTER |
What this research studies
This research investigates the use of virus-specific T-cells (VST) to treat infections caused by double-stranded DNA viruses in children who have undergone hematopoietic stem cell transplantation (HSCT). The approach involves generating T-cells from healthy donors that are specifically targeted against viruses like adenovirus and BK polyomavirus, which are common complications after transplant. These T-cells are then infused into patients to help their immune system fight off these viral infections more effectively than traditional antiviral medications. The study aims to identify factors that influence the success or failure of this treatment, providing insights into optimizing patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who have undergone hematopoietic stem cell transplantation and are experiencing viral infections.
Not a fit: Patients who are not undergoing HSCT or who do not have viral infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the morbidity and mortality associated with viral infections in pediatric patients after stem cell transplants.
How similar studies have performed: Previous clinical trials have shown that virus-specific T-cell therapy is safe and effective for treating viral infections in transplant patients, indicating a promising approach.
Where this research is happening
Cincinnati, United States
- Cincinnati Childrens Hosp Med Ctr — Cincinnati, United States (Active)
Researchers
- Principal investigator: Rubinstein, Jeremy D — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Rubinstein, Jeremy D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.